海普瑞(09989.HK)今年度計劃向各家銀行申請綜合授信額度逾33億人幣
海普瑞(09989.HK)公布,為滿足公司及子/孫公司經營及業務發展需求,公司及全資子公司美國海普瑞、香港海普瑞、全資孫公司天道醫藥、 天道香港、SPL於2021年度計劃向各家銀行申請綜合授信額度(含到期授信續期),涉資共33.09億元人民幣(下同),額度佔上市公司最近一期資產比例為28.61%。 此外,公司和子/孫公司擬就該部份授信額度向銀行提供擔保。
截至2020年末,公司及子/孫公司合計獲得銀行授信約98.61億元,實際使用額度約37.42億元。(ta/a) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.